DEVELOPING
INNOVATIVE
ORAL THERAPIES
FOR AUTOIMMUNE, INFLAMMATORY,
AND NEURODEGENERATIVE DISEASES

We focus on autoimmune, inflammatory, and neurodegenerative diseases with high unmet need

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases. Our inflammatory bowel disease portfolio includes tamuzimod, an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.

Science

Modulating key autoimmune and inflammatory pathways with broad therapeutic potential

Pipeline

Learn about our differentiated clinical-stage candidates
VTX3232 inhibiting NLRP3 inflammasome
Developing oral medicines targeting the immune system

Careers

We are passionate about developing novel therapies to improve the lives of patients

News